Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Next Previous
Search
Trial Profile

A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Alpelisib (Primary) ; Capivasertib (Primary) ; Elacestrant (Primary) ; Everolimus (Primary) ; Palbociclib (Primary) ; Ribociclib (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ELEVATE
  • Sponsors Stemline Therapeutics

    • Most Recent Events

    • 18 Feb 2025 Planned End Date changed from 31 Aug 2026 to 28 Dec 2028.
    • 18 Feb 2025 Planned primary completion date changed from 31 Dec 2024 to 27 Dec 2026.
    • 25 Nov 2024 According to a Menarini media release, update from this study will be presented as a poster on Thursday, December 12, 7-8:30 AM CST at the upcoming 2024 San Antonio Breast Cancer Symposium (SABCS), December 10-13, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top